Drugs Made In America Acquisition Corp. (DMAAR) Income towards Parent Company (2025 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Income towards Parent Company for 2 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income towards Parent Company fell 24.54% year-over-year to $1.7 million; the trailing twelve-month figure through Jun 2026 stood at $6.4 million (changed N/A YoY), and the FY2025 full-year result was $5.9 million, up 2222.83% from the prior year.
• Income towards Parent Company grew to $1.7 million in Q2 2026 per DMAAR's latest filing, from $212958.0 in the prior quarter.
• Across five years, Income towards Parent Company topped out at $2.3 million in Q2 2025 and bottomed at $212958.0 in Q4 2025.